Suummary Several in vitro studies stress a potentially important role of interleukin 4 (IL-4) and the related gp200-MR6 molecule in the immunological response to cancer and in tumour proliferation. In the present study, we assessed the expression of gp200-MR6 in primary breast cacrinomas using the MR6 monoclonal antibody. Results were correlated with tumour parameters (T-,N-stage, histology, grade, oestrogen and epidermal growth factor (EGF) receptors), and the impact on survival was assessed. Twenty-four out of 110 cases (22%) were positive for gp200-MR6, 62 out of 110 (56%) expressed weak staining and 24 out of 114 (22%) did not stain. The normal breast epithelia were invariably stained for gp200-MR6 showing that downregulation or loss of this molecule occurred during the evolution of breast cancer. Gp200-MR6 loss was independent from differentiation, nodal positivity and oestrogen receptor levels as well as patients' age. Loss of the gp200-MR6 molecule was more frequent in lobular cases (P=0.03). The overall survival was better, although not reaching statistical significance, in patients with positive gp200-MR6 expression (92% alive at 5 years compared with 70% for those with weak or no expression, P=0.1). The local relapse-free survival was independent of gp200-MR6 status. It is concluded that loss of gp200-MR6 may be one of the mechanisms through which breast cancer cells escape immune surveillance, resulting in an increased metastatic potential and poorer outcome. Evidence of down-regulation of the gp200-MR6 molecule has implications for IL-4-linked toxin therapy and, as IL-4 is an inhibitor of breast epithelial growth, may represent loss of a tumoursuppression mechanism.
Recent studies have revealed an important role of interleukin 4 (IL-4) and its receptor in carcinogenesis, tumour proliferation and the immune response against cancer. is a member of the cytokine family with-multifunctional activities on a variety of cell lines. Initially, IL-4 was described as a B-cell growth factor (Howard et al., 1982) , but subsequent studies showed a wide spectrum of activities on T lymphocytes, macrophages, granulocytes and epithelial cells (O'Hara et al., 1987; Monroe et al., 1988; Thornhill et al., 1990; Toi et al., 1991) . Accumulating data from transfection assays with the IL-4 gene or treatment of cell lines with IL-4 show that IL-4 has a potent anti-tumoral activity. In a recent study, IL-4 was proved to be a potent inhibitor of the B.16 melanoma cell line in mice and was 30% more potent than IL-2 (Zaloom et al., 1993) . Transfection of mammary adenocarcinoma cell lines to produce IL-4 showed a correlation between IL-4 production and degree of tumour inhibition (Tepper et al., 1989) . Synergy between IL-4 and other growth inhibitors has been described (Golumbek et al., 1991) . In previous work, we showed that IL-4 and other growth inhibitors, such as transforming growth factor beta (TGF-,B) and tamoxifen, have an additive inhibitory effect on the growth of colon and breast carcinoma cell lines (Toi et al., 1992) . The potentiation of tumour necrosis factor activity in breast cancer cell lines by IL-4 has also been observed (Totpal et al., 1991; Hoon et al., 1991) .
Recent studies have shown that transfection of the IL-4 gene into Lewis lung carcinoma (LLC) cells is followed by an induction of immunity against the tumour (Golumbek et al., 1991) . The production of IL-4 from renal cancer cells induces a T-cell-dependent systemic immunity against the parental cancer, providing evidence that IL-4 gene-transfected cancer cells can be used for cancer immunotherapy (Ohira et al., 1992) . The secretion of IL-4 from NK cells, isolated from breast cancer tissue or peripheral blood of breast cancer patients, supports the hypothesis that IL-4 could have a role in the immunological surveillance of cancer (Lorenzen et al., 1991) .
Further support for the role of IL-4 in tumour development comes from studies on the IL-4 receptorassociated gp200-MR6 molecule. This molecule, identified by MAb MR6, was first described at high levels on human thymic cortical epithelium; it is also expressed on other epithelia and at low levels on cells of haemopoietic origin (T and B lymphocytes and macrophages) (DeMaagd et al., 1985; von Gaudecker et al., 1989) . Co-capping data have demonstrated an association between gp200-MR6 and the IL-4-binding chain of the IL-4R (CD124), although the MR6 antibody does not block IL-4 binding (Imami et al., 1995) . Functional studies have shown that MAb MR6 inhibits the IL-4-induced proliferation of T cells and blocks the IL-4-dependent switch to IgE production in allergen-stimulated B cells (Larche et al., 1988) . These effects are thought to result predominantly from inhibition of the expansion/function of the IL-4-secreting Th2 helper T-lymphocyte subset (Imami et al., 1994) .
These data, together with previous studies indicating that gp200-MR6 expression is lost with increasing malignancy in lung and colonic carcinoma, raise the possibility that expression of this molecule may be useful in disease prognosis, and that it may function as a tumour suppressor (Tungekar et al., 1991; Kaklamanis et al., 1992) . In breast cancer, both up-regulation and down-regulation have been reported (Al Jabaari et al., 1989; Mat et al., 1993) .
In this study, we have used the monoclonal antibody MR6 to evaluate immunohistochemically the expression of gp200-MR6 in human primary breast cancer and its significance in prognosis. Samples were also analysed for expression of oestrogen and epidermal growth factor receptors (ER and EGFR). Patients were followed clinically over several years (median follow-up time 52 months). Data were analysed in the context of a range of parameters including age at presentation, T-stage, N-stage, histology, grade, ER and EGFR expression.
Materials and methods Patients One hundred and ten primary invasive breast cancer specimens were examined. The median age of our patients was 53 years and a median follow-up of 52 months was available (4 -7 years). All patients had no detectable metastatic disease at presentation and underwent partial mastectomy and radiotherapy or total mastectomy with axillary sampling and radiotherapy to the involved axilla. Adjuvant chemotherapy was given to 30 patients with advanced T-stage, positive lymphadenopathy or with poor prognostic factors such as ER-/EGFR+ and high grade. Tamoxifen was given in patients with positive oestrogen receptor levels (> 10 fmol mg-'). Patients were regularly followed clinically every 3 months for the first year, 4-monthly for the second year and 6-monthly thereafter.
Tissues
All tissues were snap frozen in liquid nitrogen and stored at -70°C. Eighty-one tumours were infiltrative ductal carcinomas and 12 were lobular carcinomas, the remaining being of different histological subtypes. Histological diagnosis and staging were assessed by light microscopy before immunohistochemistry.
Antibody MR6 immunohistochemistry
The monoclonal antibody MR6 is an IgE mouse reagent that was raised against an extract of human thymic tissus and shown to react strongly with thymic cortical epithelial cells (De Maagd et al., 1985) . Using Western blotting, MR6 detects a single polypeptide of 200 kDa. Antibody co-capping and functional blocking studies have shown an association between gp200-MR6 and the CD124 chain of the IL-4R (Larche et al., 1988; Imami et al., 1994 ; Imami et al., submitted for publication).
MR6 antibody was detected by means of the alkaline phosphatase-anti-alkaline phosphatase method (APAAP), as described previously (Cordell et al., 1984 (Figure la) . Infiltrating lymphocytes, macrophages and myoepithelial cells (Figure lb) invariably showed a positive reactivity.
Twenty-four out of 110 cases (22%) of all breast carcinomas were positive for gp200-MR6, 62 out of 110 (56%) expressed weak staining and 24 out of 114 (22%) did not stain with the MR6 antibody. Sixteen out of 81 (20%) invasive ductal carcinomas and 1 out of 12 (8%) lobular carcinomas were positively stained for gp200-MR6, showing a higher incidence of gp200-MR6 loss in lobular histology (P = 0.03). All three medullary, 1 out of 1 mucinous and 3 out of 12 mixed (ductal/lobular) cases had a strong reactivity for MR6. Figure Ic Figure ld shows a gp200-MR6-negative case, whereas normal epithelium is positively stained. Table I shows the relationship between gp200-MR6 expression and different tumour variables and patients' age. No statistically significant correlation was found between the expression of gp200-MR6 and T-stage, N-stage, grade and oestrogen receptors. Six out of 24 (25%) gp200-MR6-negative cases had positive EGFRs compared with 12 out of 24 (50%) cases expressing strong MR6 reactivity (P = 0.09). Tumour samples from women both younger and older than 50 years had similar expression of gp200-MR6.
Relationship of gp200-MR6 loss to survival A univariate analysis of overall survival showed that the most important prognostic factor was the nodal status (P<0.0001) followed by T-stage (P= 0. Figure 2a shows the Kaplan-Meier overall survival curves for three groups of gp200-MR6 staining. Strong positive staining was correlated with better survival, which was not significant on the log-rank test (P = 0.10). The local relapsefree survival was not different among groups (P=0.81) (Figure 2b ). The distant metastases-free survival was not significantly different, although it was better in cases with strong gp200-MR6 expression (P = 0.18) (Figure 2c ). Analysis of gp200-MR6 expression in node-positive and -negative cases separately showed no effect on survival.
Discussion
Elevated expression of IL-4R has been reported in a variety of tumour cell lines such as sarcomas and melanomas (Puri et al., 1991; Obiri et al., 1994) . In a preliminary study, Al Jabaari et al. (1989) analysed the expression of MR6 on a variety of normal and malignant tissues. Normal tissues showed a negative or a weak positivity to MR6, and a variety of different types of tumour tissues analysed were found to be strongly positive. In that study, preliminary immunoscintigraphical data were also presented, suggesting that MR6 may prove to be useful for in vivo imaging and targeting immunotherapy.
More recently, we have reported in further detail on the expression of gp200-MR6 in lung (Tungekar et al., 1991) , colon (Kaklamanis et al., 1992) and bladder (Tungekar et al., 1996) . In lung and colon, the expression of gp200-MR6 was found to decrease with malignancy, and 30% of squamous cell and adenocarcinoma lung cases were MR6-negative, whereas all ten small-cell lung carcinomas were negative. Positive staining was observed in 40 out of 44 colorectal carcinomas, whereas all bladder carcinoma samples retained their MR6 positivity. Thus, gp200-MR6 loss is associated with malignancy in some but not all tumour cell lineages. In breast cancer, it was found that approximately 50% of breast carcinomas (24% of in situ, 69% of invasive tumours) had reduced expression (Mat et al., 1993) .
In this study, we have examined the expression of gp200-MR6 in a large series of breast primary carcinomas to assess the distribution of this molecule in greater detail and to determine its significance in disease prognosis. Positive staining (strong and weak) was observed in 86 out of 110 (78%) cases, while 24 out of 110 (22%) exhibited strong positivity. This distribution of expression is in good agreement with a previous study (Mat et al., 1993) .
Menopausal status, tumour size, differentiation, nodal status and oestrogen receptors were not correlated with gp200-MR6 expression. These data suggest that gp200-MR6 status is not correlated with other known prognostic factors. A lower risk for distant metastases was observed in patients with positive gp200-MR6 expression. Taking into account our observations that MR6 stains normal breast, colon and lung epithelia, our data show that gp200-MR6 loss occurs during cancer evolution. As the IL-4 receptor is the target of produced by NK cells in breast cancer patients (Lorenzen et al., 1991) , it seems likely that loss of the IL-4R-associated gp200-MR6 'molecule could represent a mechanism of tumour escape from immune surveillance. IL-4R is also relevant for IL-4/toxin therapy (Debinski et al., 1993) and IL-4 is used as a growth inhibitor. Like TGF, endogenous IL-4 may be inhibitory in normal tissues, and loss of IL-4 receptor or gp200-MR6 may be related to progression.
In a recent study, we showed an increased HLA class I antigenic loss in breast cancer metastatic to lymph nodes compared with the primary tumours (Kaklamanis et al., 1995) . It would be of interest to examine whether cells metastatic to lymph nodes or distant organs have a similarly higher occurrence of gp200-MR6 loss. Short-term distant metastasisfree survival was better in patients with MR6-positive tumours. The combined role of HLA class I and IL-4R/gp200-MR6 in survival of breast cancer patients requires further investigation.
Although expression of gp200-MR6 on normal epithelia and haemopoietic cells raises potential problems of toxicity for the use of radiolabelled and toxin-conjugated antibody and cytokine targeting (Al Jabaari et al., 1989; Debinski et al., 1993) , the differences in IL-4R structure on these different cell types may negate such problems (Murata et al., 1996; Bamborough et al., 1993) . Finally, although there are many prognostic factors in breast cancer, none of them relate to immunological pathways; the data presented in this study suggest the potential of lymphokines as an infdependent pathway regulating cancer growth.
